About MicroByre
MicroByre is a company based in San Francisco (United States) founded in 2017 by Margaret Brown and Sarah Richardson. MicroByre has raised $7.67 million across 4 funding rounds from investors including Climate Capital, Prime Impact Fund and Bioeconomy Capital. MicroByre operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter San Francisco, United States
- Founders Margaret Brown, Sarah Richardson
- SectorsHealthcare
- Website microbyre.com
- Social LinkedIn X Facebook
- Total Equity Funding$7.67M (USD)
in 4 rounds
- Latest Funding Round$2.5M (USD), Seed
Oct 2021
- InvestorsClimate Capital
& 2 more
Funding Insights of MicroByre
MicroByre has successfully raised a total of $7.67M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $2.5 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.67M
- Total Rounds 4
- Last Round Seed — $2.5M
- First Round $3M
(Apr 2019)
- Investors Count 3
All 4 funding rounds of MicroByre with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $2.5M | Seed | – | – | – |
| Jun 2021 | – | Seed | – | Climate Capital | – |
| Sep 2020 | $2.17M | Seed | – | – | – |
| Apr 2019 | $3M | Seed | – | Prime Impact Fund, Bioeconomy Capital | – |
3 investors in total: 3 institutional.
Investors in MicroByre
MicroByre has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Climate Capital, Prime Impact Fund and Bioeconomy Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is invested in climate tech startups and entrepreneurs. | – | climatecapital.co | San Francisco, United States | |
Prime Impact Fund is focused on climate technology investments. | – | primeimpactfund.com | Cambridge, United States | |
- | – | bioeconomycapital.com | - |
Investor details for MicroByre
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MicroByre
4 people are tracked at MicroByre (2 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Margaret Brown | Co-Founder | Leadership |
Sarah Richardson | Co-Founder & CEO | Leadership |
Lasana Power | Research Associate II | Team |
Bryan Delgado | UI & UX Full Stack Developer | Team |
Complete people profiles for MicroByre
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MicroByre
3 dated milestones of MicroByre across 4 years, from founding to its latest funding, stage changes and deals.
- Founded MicroByre is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Seed, of $2.5M.
Competitors of MicroByre
MicroByre operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of MicroByre
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to MicroByre
10 companies that operate in the same segment as MicroByre (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MicroByre
MicroByre was founded in 2017 and raised its 1st funding round 2 years after it was founded.
MicroByre is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sarah Richardson is the current CEO of MicroByre. They have also founded this company.
MicroByre is a funded company, having raised a total of $7.67M across 4 funding rounds to date. The company's 1st funding round was a Seed of $3M, raised on Apr 2019.
MicroByre was founded in 2017 in San Francisco, United States, within the biotechnology sector. Genetically modified microorganisms are engineered by the company to serve as biomanufacturing platforms, transforming non-model species into tractable strains. Streptococcus thermophilus bacteria have been modified specifically for cheese and yogurt production. Operations focus on genetic engineering techniques to enhance industrial applications in food manufacturing.
MicroByre's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
MicroByre has 3 investors. Key investors include Climate Capital, Prime Impact Fund, and Bioeconomy Capital.